 
|
|
|
LECTURES
|
| Thursday, September 15, 2005 |
| Time |
Title |
|
|
|
| 6:00 |
Informal Dinner |
|
|
|
 |
| Friday, September 16, 2005 |
| Time |
Title |
Speaker |
|
|
|
| 8:30 |
Welcoming Remarks
|
Michaele Christian, M.D. |
|
|
| Jorge Gomez, M.D., Ph.D. |
|
|
| Patricia Goldman |
|
|
| Larry Copeland, M.D. |
|
|
| Beth Karlan, M.D. |
|
|
|
| 8:45 |
Introductions |
Michael Bierrer ,
M.D., Ph.D. |
|
|
| Jane Fountain, Ph.D. |
|
|
| Ted Trimble, M.D., M.P.H |
|
|
|
|
SESSION
1: BIOMARKERS AND TRIAL DESIGN
|
|
| 9:00 |
Co-Chairs: |
Robert Bast, M.D.
Michael Birrer, M.D. |
|
|
| |
Speakers: |
Jeff Boyd, Ph.D. |
|
|
| |
|
Robert Bast, M.D. |
|
|
| |
Topics:
Relevant biomarkers for the stratification of patients with ovarian cancer, prognostic markers, predictive markers, surrogate markers, tissue banking needs, core laboratories for multi-institutional trials, future trial design Phase II and Phase III
|
|
|
| |
Discussion |
|
|
|
|
|
SESSION
2: RELEVANT MOLECULAR MARKERS AND TARGETS
|
|
| 10:30 |
Co-Chairs: |
Robert Burger, M.D.
Russel Schilder, M.D. |
|
|
| |
Speakers: |
Anil Sood, M.D.
|
|
|
| |
|
Andrew Godwin, Ph.D. |
|
|
| |
Topics:
"Activated" pathways in ovarian cancer, potential targets, available small molecule inhibitors, immune response modifiers, needed laboratory and clinical studies
|
|
|
| |
Discussion |
|
|
|
|
|
SESSION
3: PROMISE AND PROBLEMS OF TRANSLATIONAL RESEARCH
|
|
|
| 11:30 |
Co-Chairs: |
Doris Benbrook, Ph.D.
Beth Karlan, M.D. |
|
|
| |
Speakers: |
Bill Beck, Ph.D. |
|
|
| |
|
Robert Ozols, Ph.D. |
|
|
| |
Topics:
The present infrastructure available to conduct translational research associated with ovarian cancer treatment trials, ways to improve collaboration |
|
|
| |
Discussion |
|
|
|
|
SESSION
4: NOVEL APPROACHES TO IP THERAPY
|
|
|
| 2:00 |
Co-Chairs: |
Gillian Thomas, M.D.
Deb Armstrong, M.D.
Ted Trimble, M.D., M.P.H.
|
|
|
| |
Speakers: |
Ronnie Alvarez, M.D. |
|
|
| |
|
Jerry Collins, Ph.D. |
|
|
| |
Topics:
Integrating IP/IV regimens into Phase III clinical trials for women with stage III disease, novel approaches, new agents and combinations |
|
|
| |
Discussion |
|
|
|
|
|
SESSION 5: THE FUTURE OF PHASE II TRIALS |
|
|
| |
Co-Chairs: |
Michaele Christian, M.D.
David Spriggs, M.D. |
|
|
| |
Speakers: |
Janet Dancey, M.D. |
|
|
| |
|
Michael Bookman, M.D. |
|
|
| |
|
Judy Wolf, M.D. |
|
|
| |
Topics:
How to complete Phase II trials faster; stratification of patients in Phase II trials, response end points; competition between NCI-sponsored and industry-sponsored Phase II trials for patients |
|
|
| |
Discussion |
|
|
| |
| Saturday, September 17, 2005 |
|
|
SUMMARY AND DISCUSSION OF RECOMMENDATIONS
FROM SESSIONS 1 THROUGH 5 |
|
|
| |
| Time |
Title |
Speaker |
|
|
| 8:00 |
Summary and Discussion of Recommendations |
Ted Trimble, M.D. |
|
|
| 10:30 |
Adjournment
|
|
|
|
|
